Our Services
Medical Information
Helpful Resources
Published on: 9/12/2026
Fatigue from GLP-1 medications like semaglutide, tirzepatide, and liraglutide most often begins within the first days after starting treatment or increasing a dose, and it usually eases within a few days to several weeks as your body adjusts, with most people improving by the 4 to 6 week mark. How long it lasts depends on your dose schedule, calorie and protein intake, hydration, blood sugar changes, and whether an unrelated issue such as anemia or thyroid dysfunction is contributing, so timelines vary from person to person. Fatigue that persists beyond a couple of months, worsens, or comes with dizziness, fainting, severe nausea, or rapid heartbeat deserves prompt medical attention rather than watchful waiting. There are several important factors and warning signs to weigh before assuming your tiredness is a normal side effect, so review the complete details below.
Because ongoing fatigue can signal dehydration, undereating, low blood sugar, or a separate medical condition that mimics a routine GLP-1 side effect, a free, instant, online symptom check can help you sort out likely causes in minutes and show you clear next steps, including whether to adjust course with your prescriber or seek care sooner.
Last reviewed for medical accuracy: 09/12/2026
Glucagon-like peptide-1 (GLP-1) receptor agonists—a class of medications often prescribed for type 2 diabetes and weight management—can cause a range of side effects. One common complaint is fatigue. If you’ve started a GLP-1 medication and find yourself feeling more tired than usual, you’re not alone. Below is an overview of how long fatigue typically lasts, why it happens, and what you can do to manage it.
Fatigue is more than just feeling sleepy or drowsy. It’s a sense of persistent tiredness or exhaustion that doesn’t go away with rest. Key points:
GLP-1 drugs (e.g., semaglutide, liraglutide) work by mimicking a natural gut hormone. This helps control blood sugar, slow stomach emptying, and curb appetite. Fatigue can stem from:
While everyone responds differently, clinical experience and patient reports indicate:
Keep in mind:
Several variables can affect how long fatigue lasts:
You don’t have to power through fatigue alone. Here are actionable strategies:
Hydration
Balanced Nutrition
Gradual Dose Increases
Gentle Exercise
Quality Sleep
Monitor Blood Sugar
Stress Management
Mild to moderate fatigue is expected, but certain signs warrant medical attention:
If you’re unsure whether your symptoms are serious, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you clarify your next steps and decide if you need to see a healthcare professional.
Fatigue from GLP-1 medications is a common, usually temporary side effect. Most people find that tiredness eases within 4–8 weeks as their bodies adapt. By staying well-hydrated, eating balanced meals, moderating exercise, and prioritizing sleep, you can support your energy levels during this adjustment period.
Above all, if your fatigue feels overwhelming, persists beyond 8 weeks, or comes with worrying symptoms, speak to a doctor. They can rule out other causes, adjust your treatment plan, and ensure you’re on the safest, most effective path to better health.
(References)
* Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgrad Med. 2020 Nov;132(8):676-686. doi: 10.1080/00325481.2020.1771047. Epub 2020 Jun 16. PMID: 32543261.
* Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2. Epub 2024 May 21. PMID: 38770818; PMCID: PMC11106805.
* Engin A. Endothelial Dysfunction in Obesity and Therapeutic Targets. Adv Exp Med Biol. 2024;1460:489-538. doi: 10.1007/978-3-031-63657-8_17. PMID: 39287863.
* Nie Y, Zhang Y, Liu B, Meng H. Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis. Obes Surg. 2025 Mar;35(3):808-822. doi: 10.1007/s11695-025-07733-8. Epub 2025 Feb 13. PMID: 39948306.
* Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2. Epub 2025 Feb 18. PMID: 39963952; PMCID: PMC11834151.
* Eldor R, Avraham N, Rosenberg O, Shpigelman M, Golan-Cohen A, Cukierman-Yaffe T, Merzon E, Buch A. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen. Diabetes Care. 2025 Sep 1;48(9):1607-1611. doi: 10.2337/dc25-0690. PMID: 40673973.
* Richards R, Lunt W, Whitman M, Spaltro G, Hall R. Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study. JMIR Form Res. 2025 Sep 12;9:e81912. doi: 10.2196/81912. Epub 2025 Sep 12. PMID: 40838489; PMCID: PMC12475876.
* Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026 Mar;32(3):869-882. doi: 10.1038/s41591-026-04204-0. Epub 2026 Mar 2. PMID: 41772149; PMCID: PMC13004672.
* Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Epub 2026 Mar 28. PMID: 41903163.
* Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026 Jul 8;394:e372161. doi: 10.1136/bmj-2026-372161. Epub 2026 Jul 8. PMID: 42419792.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.